Heidenreich, Silke, Ziagkos, Dimitris, de Wreede, Liesbeth C., van Biezen, Anja, Finke, Juergen, Platzbecker, Uwe, Niederwieser, Dietger, Einsele, Hermann, Bethge, Wolfgang, Schleuning, Michael, Beelen, Dietrich W., Tischer, Johanna, Nagler, Arnon, Glass, Bertram, Maertens, Johan, Yanez, Lucrecia, Beguin, Yves, Sill, Heinz ORCID: 0000-0003-0993-4371, Scheid, Christof, Stelljes, Matthias, Ganser, Arnold, Zachee, Pierre ORCID: 0000-0002-2275-5143, Selleslag, Dominik, de Witte, Theo, Robin, Marie ORCID: 0000-0003-1388-9876 and Kroeger, Nicolaus (2017). Allogeneic Stem Cell Transplantation for Patients Age >= 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT. Biol. Blood Marrow Transplant., 23 (1). S. 44 - 53. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1523-6536

Full text not available from this repository.

Abstract

In this retrospective analysis we evaluated the outcome of 313 patients aged >= 70 years in the registry of the European Group for Blood and Marrow Transplantation with myelodysplastic syndrome (MDS; n = 221) and secondary acute myeloid leukemia (n = 92) who underwent allogeneic hematopoietic stem cell transplantation (HSCT) from related (n = 79) or unrelated (n = 234) donors. Median age at HSCT was 72 years (range, 70 to 78). Conditioning regimen was nonmyeloablative (n = 54), reduced intensity (n = 207), or standard intensity (n = 52). Allogeneic HSCT for MDS patients >= 70 years was increasingly performed over time. Although during 2000 to 2004 only 16 patients received HSCT, during 2011 to 2013 the number of transplantations increased to 181. The cumulative incidence of nonrelapse mortality at 1 year and relapse at 3 years was 32% and 28%, respectively, with a 3-year overall survival rate of 34%. Good performance, determined by Karnofsky performance status, and recipients' seronegativity for cytomegalovirus was associated with 3-year estimated overall survival rates of 43% (P =.01) and 46% (P =.002), respectively. Conditioning intensity did not impact survival. After careful patient selection, allogeneic HSCT can be offered to patients older than >= 70 years with MDS. (C) 2017 American Society for Blood and Marrow Transplantation.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Heidenreich, SilkeUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ziagkos, DimitrisUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
de Wreede, Liesbeth C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
van Biezen, AnjaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Finke, JuergenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Platzbecker, UweUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Niederwieser, DietgerUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Einsele, HermannUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bethge, WolfgangUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schleuning, MichaelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Beelen, Dietrich W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tischer, JohannaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Nagler, ArnonUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Glass, BertramUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Maertens, JohanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Yanez, LucreciaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Beguin, YvesUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sill, HeinzUNSPECIFIEDorcid.org/0000-0003-0993-4371UNSPECIFIED
Scheid, ChristofUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Stelljes, MatthiasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ganser, ArnoldUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Zachee, PierreUNSPECIFIEDorcid.org/0000-0002-2275-5143UNSPECIFIED
Selleslag, DominikUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
de Witte, TheoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Robin, MarieUNSPECIFIEDorcid.org/0000-0003-1388-9876UNSPECIFIED
Kroeger, NicolausUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-247977
DOI: 10.1016/j.bbmt.2016.09.027
Journal or Publication Title: Biol. Blood Marrow Transplant.
Volume: 23
Number: 1
Page Range: S. 44 - 53
Date: 2017
Publisher: ELSEVIER SCIENCE INC
Place of Publication: NEW YORK
ISSN: 1523-6536
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
ACUTE MYELOID-LEUKEMIA; PROGNOSTIC SCORING SYSTEM; OLDER PATIENTS; COMORBIDITY INDEX; PHASE-III; GROUP-B; AZACITIDINE; CLASSIFICATION; OUTCOMES; REGIMENSMultiple languages
Hematology; Immunology; TransplantationMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/24797

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item